PULMOKINE, INC.

Basic Information

PULMOKINE, INC.
68 QUEEN ANNE DR
SLINGERLANDS, NY, 12159-9385

http://www.pulmokine.net

Company Profile

n/a

Additional Details

Field Value
DUNS: 808479906
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 4


  1. IGF::OT::IGF Aerosolized Delivery of Anti-Tubercular Drugs

    Amount: $224,960.00

    Develop an inexpensive, easy to use, aerosolized delivery system of a combination of anti-tubercular drugs that could be used for the treatment of multi-drug resistant tuberculosis (MDR TB ). PUBLIC H ...

    SBIR Phase I 2013 Department of Health and Human Services
  2. An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper

    Amount: $2,267,504.00

    DESCRIPTION (provided by applicant): The purpose of this Phase II project is to develop a new treatment for pulmonary arterial hypertension (PAH) consisting of the inhaled platelet derived growth fact ...

    SBIR Phase II 2012 Department of Health and Human Services
  3. A novel JAK inhibitor for the treatment of pulmonary arterial hypertension

    Amount: $311,629.00

    DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is a rare disease associated with high morbidity and mortality. The purpose of this proposal is to develop a novel combined J ...

    SBIR Phase I 2010 Department of Health and Human Services
  4. A PDGFR inhibitor for the treatment of pulmonary arterial hypertension

    Amount: $351,008.00

    DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is a devastating disease associated with high morbidity and mortality. The purpose of this proposal is to develop a novel hig ...

    SBIR Phase I 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government